Sees FY23 net product revenues $1.575 billion – $1.675 billion, cost of goods sold 4.0% – 5.0% of net product revenues, research and development expenses $1.0B- $1.05B.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXEL:
- Exelixis options imply 3.8% move in share price post-earnings
- Credit Suisse Says These 2 Stocks Could Surge Over 30% From Current Levels
- Credit Suisse bullish on Exelixis, initiates with an Outperform
- Exelixis initiated with an Outperform at Credit Suisse
- William Blair says Exelixis cabozantinib patent verdict in line with expectation
